Hansen Medical Appoints Will Sutton as Chief Operating Officer Responsible for Engineering and Manufacturing

Hansen Medical Appoints Will Sutton as Chief Operating Officer Responsible for 
Engineering and Manufacturing 
MOUNTAIN VIEW, CA -- (Marketwire) -- 02/14/13 --  Hansen Medical,
Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today
announced the recent appointment of Will Sutton to the newly created
position of Chief Operating Officer. Mr. Sutton will report directly
to Bruce Barclay, President and Chief Executive Officer. His
responsibilities will include the management and oversight of the
engineering and manufacturing functions. The creation of this
position provides the benefit of enhanced collaboration on product
development and manufacturing, which is consistent with the Company's
strategic imperative to bringing new, innovative products and
capabilities to the market with improved product margins.  
Mr. Sutton brings over 25 years of product development and
manufacturing experience in the medical technology industry. Prior to
joining Hansen Medical, Mr. Sutton served in increasingly senior
positions at St. Jude Medical over the past 10 years. In his most
recent role as Vice President of Research and Development of the
Atrial Fibrillation (AF) Division, Mr. Sutton directed day-to-day and
strategic R&D activities for global interventional electrophysiology
products and was responsible for managing a department of 270
employees across five locations, as well as a portfolio of over 30
annual projects. During his six years in this role, revenue in the AF
Division of St. Jude Medical grew more than six-fold from $145
million to over $880 million. Earlier in his career at St. Jude
Medical, he served as the Director of R&D for the Cardiac Surgery
Division and Vice President of Program Management for the AF
Division, where he was responsible for overseeing day-to-day
strategic R&D activities and ensuring project performance to
timeline, budget, features, and success metrics. 
Mr. Sutton has also held multiple executive management positions in
both R&D and manufacturing at Vascular Solutions, Urologix and C.R.
Bard. He began his career as a development engineer in the
Diagnostics Division of Abbott Labs, and holds a B.S. and M.S. in
mechanical engineering from Stanford University.  
"Will has extensive operations, research, produ
ct development, and
manufacturing experience in the medical technology space, both in
capital equipment and disposables, and within both the EP and
vascular markets," said Bruce, President and CEO of Hansen Medical.
"His background is ideal for the newly created COO position. As
Hansen Medical sharpens its operational and commercial focus, it is
imperative that we have the organizational structure, and experienced
leadership to maximize profitability and ensure long-term commercial
success. Will's appointment, as well as the recently announced
appointment of Bob Cathcart to the position of Senior Vice President
of Global Sales, provides Hansen Medical with two additional, highly
experienced senior executives with proven commercial success in
support of this objective. I am confident that Will's expertise will
be invaluable to our Company as we expand the launch of our
Magellan(TM) Robotic System, and continue to advance our product
pipeline." 
"I am excited to join the Hansen Medical team at such an important
inflection point in the Company's history," said Mr. Sutton. "I look
forward to utilizing my experience in operations management,
research, product development, and manufacturing to help Hansen
Medical achieve operational and commercial excellence."  
About Hansen Medical, Inc. 
 Hansen Medical, Inc., based in Mountain
View, California, is the global leader in intravascular robotics,
developing products and technology designed to enable the accurate
positioning, manipulation and control of catheters and catheter-based
technologies. The Company's Magellan(TM) Robotic System, Magellan
Robotic Catheter and related accessories, which are intended to
facilitate navigation to anatomical targets in the peripheral
vasculature and subsequently provide a conduit for manual placement
of therapeutic devices, have undergone both CE marking and 510(k)
clearance and are commercially available in the European Union, and
the U.S. In the European Union, the Company's Sensei(R) X Robotic
Catheter System and Artisan Control Catheter are cleared for use
during electrophysiology (EP) procedures, such as guiding catheters
in the treatment of atrial fibrillation (AF), and the Lynx(R) Robotic
Ablation Catheter is cleared for the treatment of AF. This robotic
catheter system is compatible with fluoroscopy, ultrasound, 3D
surface map and patient electrocardiogram data. In the U.S. the
Company's Sensei X Robotic Catheter System and Artisan Control
Catheter were cleared by the U.S. Food and Drug Administration for
manipulation and control of certain mapping catheters in EP
procedures. In the United States, the Sensei System is not approved
for use in guiding ablation procedures; this use remains
experimental. The U.S. product labeling therefore provides that the
safety and effectiveness of the Sensei X System and Artisan Control
Catheter for use with cardiac ablation catheters in the treatment of
cardiac arrhythmias, including AF, have not been established.
Additional information can be found at www.hansenmedical.com.  
Forward-Looking Statements
 This press release contains
forward-looking statements regarding, among other things, statements
relating to goals, plans, objectives, milestones and future events.
All statements, other than statements of historical fact, are
statements that could be deemed forward-looking statements, including
statements containing the words "plan," "expects," "potential,"
"believes," "goal," "estimate," "anticipates," and similar words.
These statements are based on the current estimates and assumptions
of our management as of the date of this press release and are
subject to risks, uncertainties, changes in circumstances and other
factors that may cause actual results to differ materially from the
information expressed or implied by forward-looking statements made
in this press release. Examples of such statements include statements
about our long-term profitability and success, the progress of our
Magellan(TM) Robotic System launch, and advancement of our product
pipeline. Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements
include, among others: technical, clinical, engineering, regulatory,
manufacturing, sales and customer service challenges in developing
new products and entering new markets; potential safety and
regulatory issues that could slow or suspend our sales; the effect of
credit, financial and economic conditions on capital spending by our
potential customers; the uncertain timelines for the sales cycle for
newly introduced products; the rate of adoption of our systems and
the rate of use of our catheters; the scope and validity of
intellectual property rights applicable to our products; competition
from other companies; our ability to recruit and retain key
personnel; our ability to maintain our remedial actions over
previously reported material weaknesses in internal controls over
financial reporting; our ability to manage expenses and cash flow,
and obtain additional financing; and other risks more fully described
in the "Risk Factors" section of our Quarterly Report on Form 10-Q
for the quarter ended September 30, 2012 filed with the SEC on
November 9, 2012 and the risks discussed in o
ur other reports filed
with the SEC. Given these uncertainties, you should not place undue
reliance on the forward-looking statements in this press release. We
undertake no obligation to revise or update information herein to
reflect events or circumstances in the future, even if new
information becomes available.  
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan is a
trademark of Hansen Medical, Inc. in the United States and other
countries. 
Investor Contacts: 
Peter J. Mariani 
Chief Financial Officer 
Hansen Medical, Inc. 
650.404.5800  
FTI Consulting, Inc.
Brian Ritchie
212.850.5683 
brian.ritchie@fticonsulting.com  
John Capodanno
212.850.5705
john.capodanno@fticonsulting.com